于小津,吳秀英
丙泊酚、依托咪酯復(fù)合咪達(dá)唑侖、芬太尼用于無痛人工流產(chǎn)術(shù)的臨床研究
于小津,吳秀英*
目的 比較丙泊酚、依托咪酯復(fù)合芬太尼、咪達(dá)唑侖用于無痛人工流產(chǎn)術(shù)的麻醉效果及不良反應(yīng),探討安全、舒適的人工流產(chǎn)術(shù)麻醉方案。方法 選擇自愿行無痛人工流產(chǎn)術(shù)的女性160例(孕周6~10周),隨機(jī)分為4組(n=40):丙泊酚復(fù)合芬太尼及咪達(dá)唑侖組(PMF)、丙泊酚復(fù)合芬太尼組(PF)、依托咪酯復(fù)合芬太尼及咪達(dá)唑侖組(EMF)及依托咪酯復(fù)合芬太尼組(EF)。PMF組和EMF組于麻醉前2 min靜脈注射咪達(dá)唑侖0.02 mg/kg,PF組與EF組則靜脈注射生理鹽水1 mL作為對(duì)照;2 min后各組均靜脈推注芬太尼1 μg/kg,注射完畢2 min后,P組靜脈注射丙泊酚2 mg/kg,E組靜脈注射依托咪酯0.2 mg/kg。記錄各組入室(T1)、預(yù)給后(T2)、誘導(dǎo)期(T3)、追加期(T4)、結(jié)束時(shí)(T5)、蘇醒時(shí)(T6)的平均動(dòng)脈壓(MAP)、心率(HR)和血氧飽和度(SpO2)。并記錄誘導(dǎo)至第1次追加時(shí)間(t1)、末次給藥至睜眼時(shí)間(t2)、末次給藥至應(yīng)答時(shí)間(t3)、末次給藥至自行走動(dòng)時(shí)間(t4)、手術(shù)時(shí)間(ST)、術(shù)畢至睜眼時(shí)間(SZ);丙泊酚和依托咪酯計(jì)算總量(SUM),丙泊酚和依托咪酯經(jīng)體重、手術(shù)時(shí)間校正后的總量(SWM)及不良反應(yīng)。結(jié)果 (1) 用藥量:EMF組SUM、SWM小于EF組(P<0.05或0.01);PMF組SUM、SWM小于PF組(P<0.05或<0.01)。(2) 麻醉恢復(fù)時(shí)間:PMF組t2、t3大于PF組(P<0.01)、EMF組(P<0.01或0.05);PMF組SZ大于EMF組(P<0.01)。(3) MAP:PMF、PF、EMF、EF組T3期MAP小于T1期、T4期(P<0.01);PMF、PF、EMF、EF組T5期MAP小于T4期(P<0.01)。EF組T4期MAP高于T1期(P<0.05),PMF、PF組T6期MAP小于T1期(P<0.05或0.01)。PF、PMF、EMF組T3期MAP小于EF組(P<0.05或0.01)。(4)HR:PMF、PF、EMF、EF組T3期HR小于T1期(P<0.01)、T4期(P<0.01)。PMF、PF、EMF組T6期HR高于T3期(P<0.05)。(5)SpO2:PMF、PF、EF組T3期SpO2小于T1期(P<0.01)。EMF、EF組T3期SpO2均大于PMF、PF組(P<0.05或0.01);PMF、PF組T5期SpO2小于EF組(P<0.01)。丙泊酚組注射痛發(fā)生率顯著高于依托咪酯;依托咪酯組術(shù)中肌顫、術(shù)后惡心嘔吐的發(fā)生率顯著高于丙泊酚組,復(fù)合咪達(dá)唑侖可降低依托咪酯組上述兩種不良反應(yīng)的發(fā)生率。結(jié)論 無痛人工流產(chǎn)術(shù)期間,丙泊酚對(duì)呼吸、循環(huán)系統(tǒng)的抑制作用明顯,以誘導(dǎo)期最為突出,而依托咪酯在麻醉期間對(duì)呼吸、循環(huán)系統(tǒng)的影響較小。丙泊酚復(fù)合芬太尼、依托咪酯復(fù)合芬太尼及咪達(dá)唑侖是適于人工流產(chǎn)術(shù)的舒適、安全的麻醉方案。
無痛人工流產(chǎn)術(shù);依托咪酯;丙泊酚;咪達(dá)唑侖;不良反應(yīng)
人工流產(chǎn)術(shù)作為女性最常見的門診手術(shù)之一,全世界每年有近四千五百萬人次接受此類手術(shù)。由于術(shù)中擴(kuò)張宮頸及吸刮宮腔時(shí)疼痛明顯,加之女性獨(dú)特的心理和社會(huì)特點(diǎn)亦會(huì)影響其對(duì)疼痛的感知,故常引起孕婦不適甚至難以配合手術(shù)完成,且人工流產(chǎn)綜合征的發(fā)生率也較高。隨著人們對(duì)手術(shù)舒適性的需求不斷提高,加之近年來關(guān)于短效鎮(zhèn)靜催眠藥、鎮(zhèn)痛藥的研究不斷進(jìn)展,靜脈全身麻醉下的無痛人工流產(chǎn)術(shù)越來越受到重視。但由于靜脈麻醉藥品的呼吸、循環(huán)抑制、術(shù)后不良反應(yīng)發(fā)生率較高,故探討并采用相對(duì)安全、舒適的無痛人工流產(chǎn)術(shù)麻醉方法則尤為重要。本研究通過比較丙泊酚、依托咪酯復(fù)合芬太尼、咪達(dá)唑侖用于無痛人工流產(chǎn)術(shù)的麻醉效果及不良反應(yīng)的差異,以探討相對(duì)安全、舒適的人工流產(chǎn)術(shù)麻醉方案。
1.1 一般資料 本研究選取自愿于靜脈全身麻醉下行無痛人工流產(chǎn)術(shù)終止妊娠的女性160例,孕期6~10周,ASA Ⅰ~Ⅱ級(jí)。術(shù)前心電圖及血常規(guī)檢查正常,近2周無發(fā)熱、上呼吸道感染病史,既往無嚴(yán)重心血管系統(tǒng)和神經(jīng)系統(tǒng)疾病病史。所有入選孕婦隨機(jī)分為丙泊酚(P)組、依托咪酯(E)組,每組80例;其中P組隨機(jī)分為丙泊酚復(fù)合咪達(dá)唑侖、芬太尼組(PMF),丙泊酚復(fù)合芬太尼組(PF)2個(gè)亞組,每組40例;E組隨機(jī)分為依托咪酯復(fù)合咪達(dá)唑侖、芬太尼組(EMF),依托咪酯復(fù)合芬太尼組(EF)2個(gè)亞組,每組40例。PMF、EMF、PF、EF四組之間在年齡、身高、體重及手術(shù)時(shí)間上均無統(tǒng)計(jì)學(xué)差異(P>0.05)。
1.2 方法 所有入選孕婦術(shù)前禁食水6 h以上。入室后監(jiān)測(cè)BP、HR和SpO2,鼻導(dǎo)管吸氧2 L/min。PMF組和EMF組靜脈注射咪達(dá)唑侖0.02 mg/kg,PF組和EF組靜脈注射生理鹽水1 mL以作對(duì)照;2 min后各組均靜脈推注芬太尼1 μg/kg,注射完畢2 min后,P組靜脈注射丙泊酚2 mg/kg,E組靜脈注射依托咪酯0.2 mg/kg,且均于1 min內(nèi)注完。若術(shù)中出現(xiàn)體動(dòng),P組追加丙泊酚20~40 mg/次,E組追加依托咪酯2~4 mg/次。當(dāng)血壓波動(dòng)低于入室基礎(chǔ)值30%或收縮壓低于80 mmHg時(shí),則靜脈注射麻黃堿15 mg;當(dāng)心率<50次/min時(shí),則靜脈注射阿托品0.25 mg。當(dāng)血氧飽和度<95%或呼吸暫停時(shí),則托下頜或面罩加壓給氧。
1.3 觀察指標(biāo) 記錄各組入室(T1)、預(yù)給后(T2)、誘導(dǎo)期(T3)、追加期(T4)、結(jié)束時(shí)(T5)、蘇醒時(shí)(T6)的BP、HR和SpO2。并記錄誘導(dǎo)至第1次追加時(shí)間(t1)、末次給藥至睜眼時(shí)間(t2)、末次給藥至應(yīng)答時(shí)間(t3)、末次給藥至自行走動(dòng)時(shí)間(t4)、手術(shù)時(shí)間(ST)、術(shù)畢至睜眼時(shí)間(SZ);丙泊酚及依托咪酯計(jì)算用量(SUM)、丙泊酚及依托咪酯經(jīng)體重、手術(shù)時(shí)間校正后用量(SWM);注射痛、術(shù)中肌顫、術(shù)后惡心嘔吐的發(fā)生情況。
2.1 用藥量 EMF組SUM、SWM為[(15.78±4.21) mg,(0.040 ±0.012) mg/(min·kg)],小于EF組[(18.93±4.82) mg,(0.053±0.016) mg/(min·kg);P<0.05或<0.01];PMF組SUM、SWM為[(149.50±30.01) mg,(0.36±0.84) mg/(min·kg)],小于PF組[(175.63±28.00) mg,(0.43±0.13) mg/(min·kg);P<0.05或<0.01]。
2.2 麻醉蘇醒情況 PMF組t2、t3較PF組延長(P<0.01);PMF組 t2、t3及SZ較EMF組延長(P<0.01,P<0.05),見表1。
表1 患者追加及蘇醒時(shí)間
注:與PMF組比較,*P<0.05,**P<0.01
2.3 生命體征 (1) 平均動(dòng)脈壓(MAP):組內(nèi)比較,PMF、PF、EMF、EF組T3期MAP小于T1期、T4期(P<0.01);PMF、PF、EMF、EF組T5期MAP小于T4期(P<0.01)。EF組T4期MAP高于T1期(P<0.05),PMF、PF組T6期MAP小于T1期(P<0.05或0.01)。各組MAP隨時(shí)間變化規(guī)律見圖1。組間比較,PF、PMF、EMF組T3期MAP小于EF組(P<0.05或0.01)。見表2。(2)心率(HR):組內(nèi)比較,PMF、PF、EMF、EF組T3期HR小于T1期(P<0.01)、T4期(P<0.01)。PMF、PF、EMF組T6期HR高于T3期(P<0.05)。各組HR隨時(shí)間變化規(guī)律見圖2。組間比較均無統(tǒng)計(jì)學(xué)差異。見表2。(3) 血氧飽和度(SpO2):組內(nèi)比較,PMF、PF、EF組T3期SpO2小于T1期(P<0.01)。各組SpO2隨時(shí)間變化規(guī)律見圖3。組間比較,EMF、EF組T3期SpO2均大于PMF、PF組(P<0.05或0.01);PMF、PF組T5期SpO2小于EF組(P<0.01)。見表2。
2.4 不良反應(yīng) PMF組、PF組注射痛明顯多于EMF組、EF組(P<0.01),EMF組、EF組肌陣攣明顯多于PMF組、PF組(P<0.01),且EMF組肌陣攣較EF組輕(P<0.05)。PMF組惡心嘔吐較EMF組、EF組明顯減輕(P<0.01);PF組惡心嘔吐較EMF組、EF組明顯減輕(P<0.01);且EMF組惡心嘔吐較EF組減輕(P<0.05)。見表3。
表2 患者血流動(dòng)力學(xué)變化及血氧飽和度變化情況
注:與EF比較,*P<0.05,**P<0.01;與EMF比較,□P<0.05,□□P<0.01;與T1期比較,▲P<0.05,▲▲P<0.01;與T3期比較,△P<0.05,△△P<0.01
表3 患者不良反應(yīng)發(fā)生情況(n=40)
圖1 MAP隨時(shí)間變化規(guī)律注:與T1期比較,▲▲P<0.01,▲P<0.05;與T3期比較,△△P<0.01
圖2 HR隨時(shí)間變化規(guī)律注:與T1期比較,▲▲P<0.01;與T3期比較,△△P<0.01,△P<0.05
圖3 SpO2隨時(shí)間變化規(guī)律注:與T1期比較,▲▲P<0.01;與T3期比較,△△P<0.01
丙泊酚是一種短效、非巴比妥類靜脈麻醉藥,其確切作用機(jī)制目前暫不清楚,但有證據(jù)顯示,丙泊酚主要作用于海馬的γ-氨基丁酸A受體(GABAA),與β亞基結(jié)合,增強(qiáng)γ-氨基丁酸(GABA)誘導(dǎo)的氯電流,抑制海馬和前額葉皮質(zhì)釋放乙酰膽堿,從而產(chǎn)生催眠作用[1-3]。丙泊酚催眠作用起效迅速,且催眠作用時(shí)間呈劑量依賴性[4-5],其清除率極高,即使長時(shí)間輸注仍可迅速蘇醒,適于短小手術(shù)麻醉。依托咪酯是咪唑的衍生物,與丙泊酚同屬于短效、非巴比妥類靜脈麻醉藥。其作用機(jī)制尚不清楚,一般來說與丙泊酚基本類似[6]。此藥起效迅速,單次誘導(dǎo)劑量與作用時(shí)間呈直線相關(guān),引起意識(shí)消失的半數(shù)有效劑量(ED50)為0.11 mg/kg[7]。依托咪酯在肝臟清除率較高,無藥物蓄積作用,多次給藥或輸注后仍可迅速蘇醒。本研究觀察丙泊酚和依托咪酯的蘇醒時(shí)間發(fā)現(xiàn),丙泊酚復(fù)合芬太尼組與依托咪酯復(fù)合芬太尼組在各觀察時(shí)間上均無統(tǒng)計(jì)學(xué)差異,均可迅速蘇醒,這與此兩種藥物均具有清除率高、無蓄積作用的特點(diǎn)有關(guān)。
誘導(dǎo)劑量的丙泊酚即可引起呼吸暫停,發(fā)生率和持續(xù)時(shí)間取決于劑量、注射速度及合并用藥[10]。與丙泊酚不同的是,依托咪酯具有呼吸抑制小的特點(diǎn)。本研究觀察患者血氧飽和度的變化發(fā)現(xiàn),無論是否與咪達(dá)唑侖合用,丙泊酚誘導(dǎo)期的血氧飽和度均明顯低于依托咪酯。分析原因在于丙泊酚呼吸抑制作用較依托咪酯明顯,且合用阿片類藥物可增加呼吸抑制的發(fā)生率[10],故表現(xiàn)為丙泊酚誘導(dǎo)期血氧飽和度明顯下降。本研究對(duì)各組組內(nèi)血氧飽和度變化規(guī)律的觀察發(fā)現(xiàn),誘導(dǎo)期最容易發(fā)生呼吸抑制,而依托咪酯復(fù)合咪達(dá)唑侖、芬太尼組在四組中血氧飽和度變化最小,分析原因認(rèn)為,此同樣與依托咪酯呼吸抑制作用小、其合用少量咪達(dá)唑侖對(duì)呼吸功能不產(chǎn)生明顯影響有關(guān)。本研究觀察合用咪達(dá)唑侖對(duì)丙泊酚、依托咪酯血氧飽和度的影響發(fā)現(xiàn),依托咪酯、芬太尼合用并未因再復(fù)合使用咪達(dá)唑侖而導(dǎo)致明顯的血氧飽和度變化,雖然咪達(dá)唑侖同樣具有呼吸抑制作用,但其程度與劑量相關(guān)[11],本研究預(yù)注射咪達(dá)唑侖用量小,僅為1/5 ED50,其呼吸抑制作用可能尚未表現(xiàn)。
丙泊酚可產(chǎn)生較明顯的循環(huán)抑制,最顯著體現(xiàn)在誘導(dǎo)期平均動(dòng)脈壓的降低[12]。而依托咪酯具有血流動(dòng)力學(xué)平穩(wěn)[13]的特點(diǎn),依托咪酯的血流動(dòng)力學(xué)穩(wěn)定性與其不影響交感神經(jīng)系統(tǒng)和壓力感受器功能有一定關(guān)系[14]。本研究中各組誘導(dǎo)期平均動(dòng)脈壓均較入室下降,追加期均較誘導(dǎo)期升高,僅依托咪酯復(fù)合芬太尼組(EF組)追加期高于入室,其余無明顯差異。認(rèn)為依托咪酯對(duì)循環(huán)抑制輕,在無咪達(dá)唑侖復(fù)合使用的情況下,直接反映了追加期因藥物代謝引起的麻醉減淺、刺激相對(duì)強(qiáng)烈所致的平均動(dòng)脈壓增高,表現(xiàn)為追加期平均動(dòng)脈壓升高明顯且高于入室;而丙泊酚則由于循環(huán)抑制明顯,降低的平均動(dòng)脈壓抵消了部分因麻醉減淺而導(dǎo)致的平均動(dòng)脈壓升高,故僅表現(xiàn)為追加期平均動(dòng)脈壓較誘導(dǎo)期有所升高,但與入室差異無統(tǒng)計(jì)學(xué)意義。不合用咪達(dá)唑侖時(shí),丙泊酚的誘導(dǎo)期平均動(dòng)脈壓較依托咪酯低。認(rèn)為這同樣與丙泊酚循環(huán)抑制明顯、依托咪酯血流動(dòng)力學(xué)平穩(wěn)的特點(diǎn)有關(guān)。
本研究中各組誘導(dǎo)期心率均較入室下降,追加期均較誘導(dǎo)期升高,但與入室差異無統(tǒng)計(jì)學(xué)意義。除依托咪酯復(fù)合芬太尼組(EF組)外,其余各組蘇醒期心率均較誘導(dǎo)期上升。與平均動(dòng)脈壓變化綜合分析,對(duì)于誘導(dǎo)期血壓下降明顯的丙泊酚組而言,在誘導(dǎo)期血壓明顯下降的同時(shí),心率并未升高反而隨之下降,其原因可能是由于丙泊酚重置或抑制壓力感受器反射,從而減弱了機(jī)體對(duì)低血壓的心動(dòng)過速反應(yīng)[15]。與此同時(shí),由于丙泊酚的循環(huán)抑制作用明顯,在蘇醒期血壓仍處于較低水平,為維持有效的心排出量,故表現(xiàn)為代償性心率增快。
丙泊酚和依托咪酯在靜脈注射時(shí)均可引起注射痛,并偶爾可引起注射靜脈血栓性靜脈炎。但由于近年依托咪酯的新劑型—脂質(zhì)乳劑的使用,已大大減少了其注射痛的發(fā)生率[16]。本研究中丙泊酚引起注射痛明顯多于依托咪酯,且預(yù)注射咪達(dá)唑侖并不影響丙泊酚及依托咪酯注射痛的發(fā)生情況。
目前,越來越多的證據(jù)表明,丙泊酚亦具有止吐作用,但機(jī)制暫不明,可能由于丙泊酚具有廣泛的中樞神經(jīng)抑制作用或其可直接抑制催吐化學(xué)感受區(qū)、迷走神經(jīng)核或其他未知嘔吐中樞,或可減少與鎮(zhèn)吐有關(guān)的興奮性氨基酸的釋放。而依托咪酯術(shù)后惡心嘔吐的發(fā)生率則較高,為30%~40%。本研究中,丙泊酚組較依托咪酯組發(fā)生惡心嘔吐的情況明顯減輕,且預(yù)注射咪達(dá)唑侖可減輕使用依托咪酯時(shí)發(fā)生的惡心嘔吐。這可能與咪達(dá)唑侖與依托咪酯合用產(chǎn)生協(xié)同作用從而加強(qiáng)鎮(zhèn)靜效果,減少由于情緒波動(dòng)及手術(shù)刺激應(yīng)激所產(chǎn)生的惡心嘔吐。
總之,無痛人工流產(chǎn)術(shù)期間,丙泊酚對(duì)呼吸、循環(huán)系統(tǒng)的抑制作用明顯,以誘導(dǎo)期最為突出,而依托咪酯麻醉期間對(duì)呼吸、循環(huán)系統(tǒng)的影響較小。丙泊酚組注射痛發(fā)生率顯著高于依托咪酯組;依托咪酯組術(shù)中肌陣攣、術(shù)后惡心嘔吐的發(fā)生率顯著高于丙泊酚組,復(fù)合咪達(dá)唑侖可降低依托咪酯上述兩種不良反應(yīng)的發(fā)生率。丙泊酚復(fù)合芬太尼、依托咪酯復(fù)合芬太尼及咪達(dá)唑侖是適于人工流產(chǎn)術(shù)的舒適、安全的麻醉方案。
[1] Jurd R,Arras M,Lambert S,et al.General anesthetic actions in vivo strongly attenuated by a point mutation in the GABAA receptor beta3 subunit[J].FASEB J,2003,17:250-252.
[2] 蘇保義,黃惠勇,朱旭.丙泊酚聯(lián)合鹽酸奧布卡因凝膠在人工流產(chǎn)術(shù)中的應(yīng)用[J].實(shí)用醫(yī)學(xué)雜志,2012,28(21):3673-3674.
[3] 黃守印,岳修勤.地佐辛復(fù)合丙泊酚用于無痛人工流產(chǎn)術(shù)的最佳劑量探討[J].中國醫(yī)師雜志,2012,14(9):1171-1174.
[4] 楊柳,陽國平,黃潔,等.丙泊酚注射液在健康志愿者中的藥代動(dòng)力學(xué)與藥效學(xué)[J].中國臨床藥理學(xué)雜志,2013(2):58-60.
[5] Puri A,Medhi B,Panda NB,et al.Propofol pharmacokinetics in young healthy Indian subjects[J].Indian J Pharmacol,2012 May-Jun,44(3):402-406.
[6] Joseph F.Cotten,Douglas E.Raines.Toward a Better Etomidate[J].ICU Director,2013,4(3):115-120.
[7] 任三姐,張馬忠,王珊娟.患者靜脈輸注依托咪酯的群體藥代動(dòng)力學(xué)[J].中華麻醉學(xué)雜志,2013,5:148-153.
[8] Gao X,Cook JA.The effects of CYP3A inhibitors on sildenafil and midazolam pharmacokinetics are highly correlated[C].Clinical Pharmacology & Therapeutics,2013,93:S18.
[9] 朱霞玲.丙泊酚聯(lián)合咪達(dá)唑侖在無痛人流中的應(yīng)用[J].實(shí)用藥物與臨床,2013,16(1):31-32.
[10]Sanderson JH,Blades JF.Multicentre study of propofol in day case surgery[J].Anaesthesia,1988,43(Suppl):70-73.
[11]趙劍斌,葉建亮.咪達(dá)唑侖和丙泊酚對(duì)ICU病人的臨床效果觀察[J].中國臨床醫(yī)生,2010,38(10):32-34.
[12]Larsen R,Rathgeber J,Bagdahn A,et al.Effects of propofol on cardiovascular dynamics and coronary blood flow in geriatric patients.A comparison with etomidate[J].Anaesthesia,1988,43:25-31.
[13]Lopatka CW,Muzi M,Ebert TJ.Propofol,but not etomidate,reduces desflurane-mediated sympathetic activation in humans[J].Can J Anaesth,1999,46(4):342-347.
[14]Ebert TJ,Muzi M,Berens R,et al.Sympathetic responses to induction of anesthesia in humans with propofol or etomidate [J].Anesthesiology,1992,76:725-733.
[15]Ebert TJ,Muzi M,et al.Sympathetic responses to induction of anesthesia in humans with propofol or etomidate [J].Anesthesiology,1992,76:725-733.
[16]Doenicke AW,Roizen MF,Hoernecke R,et al.Solvent for etomidate may cause pain and adverse effects [J].Br J Anaesth,1999,83:464-466.
[17]韓沖芳,屈天昉,聶麗霞.依托咪酯脂肪乳用于全憑靜脈麻醉的效果評(píng)價(jià)[J].山西醫(yī)科大學(xué)學(xué)報(bào),2010,(6):66-68.
[18]趙曉虹,李金寶,鄧小明,等.雷米芬太尼預(yù)處理減少依托咪酯所致肌陣攣[J].臨床麻醉學(xué)雜志,2008,6,24(6):482-483.
Clinical effect of propofol,etomidate combined with midazolam,fentanyl on painless induced abortion
YU Xiao-jin,WU Xiu-ying*
(Department of Anesthesiology,Shengjing Hospital of China Medical University,Shenyang 110004,China)
Objective To compare the anesthetic effect and the adverse reactions of propofol and etomidate,which were combined with fentanyl or midazolam,to instruct the safe and comfortable induced abortion anaesthesia program.Methods 160 ASA Ⅰ or Ⅱ patients undergoing painless induced abortion were randomly divided into four groups(n=40):Group PF,PMF,EF and EMF.Group PMF and EMF
midazolam at 0.02 mg/kg,then Group PF and EF received normal saline 1 mL as placebo.After two minutes,all of them received fentanyl 1 μg/kg.Two minutes after being injected fentanyl,Group PF and PMF received propofol at 2 mg/kg,Group EF and EMF received etomidate at 0.2 mg/kg.When the body movements appeared in the operation,Group PF and PMF were injected propofol 20~40 mg per time,Group EF and EMF were injected etomidate 2~4 mg per time.MAP,HR and SpO2were recorded at 6 time points,which were before anesthesia(T1),after the injection of midazolam or placebo(T2),after the injection of propofol or etomidate(T3),after the additional injection of propofol or etomidate(T4),when the operation being finished(T5),when the patients recovered(T6).Recovery time was recorded,which was stated as follows:the time from induction to the first additional injection(t1),the time from the last injection to the moment patients could open eyes (t2),the time from the last injection to the moment patients could answer (t3),the time from the last injection to the moment patients could walk by themselves (t4),the time from operation finished to the moment patients could open eyes (SZ),the operation time (ST).The calculating dosage of propofol or etomidate(SUM),the dosage of propofol or etomidate after the correction of operation time and weight (SWM),adverse reactions were all recorded.Results SUM and SWM of Group EM were lower than those of Group EF(P<0.05 or 0.01);SUM and SWM of Group PMF were lower than those of Group P (P<0.05 or 0.01).The t2 and t3 of Group PMF were longer than those of Group PF(P<0.01 or 0.05),and Group EMF(P<0.01 or 0.05);The SZ of Group PMF were longer than that of Group EMF (P<0.01).MAP of Group PMF、PF、EMF and EF at T3 were lower than those of T1 and T4 (P<0.01);MAP of Group PMF、PF、EMF and EF at T5 were lower than those of T4 (P<0.01).MAP of Group EF at T4 was higher than those of T1 (P<0.05),MAP of Group PMF and PF at T6 were lower than those of T1 (P<0.05 or <0.01).MAP of Group PF、PMF and EMF at T3 were lower than that of Group EF(P<0.01 or <0.05).HR of Group PMF、PF、EMF、EF at T3 were lower than those of T1 and T4 (P<0.01).HR of Group PMF、PF、EMF at T6 were higher than those of T3 (P<0.05).SpO2of Group PMF、PF、EF at T3 were lower than those of T1(P<0.01).SpO2of Group EMF and EF at T3 were higher than that of Group PMF and PF(P<0.05 or <0.01);SpO2of Group PMF and PF at T5 were lower than Group EF(P<0.01).The pain of injection was higher by using propofol than using etomidate.Although etomidate would cause myoclonus and nausea & vomit after operation,combined with midazolam would reduce them.Conclusion During the painless induced abortion,the inhibition of the respiratory and circulatory system of propofol is obvious,especially in the induction process.However,it is much less by using etomidate.The anaesthesia programs which constituted by propofol and fentanyl,or etomidate,fentanyl and midazolam are all comfortable and safe.
Painless artificial abortion;Etomidate;Propofol;Midazolam;Side effects
2013-07-12
中國醫(yī)科大學(xué)附屬盛京醫(yī)院麻醉科,沈陽 110004
*通信作者